The frequency of PSA-reactive precursor cells in the patients' circulation after therapy ranged from 1 out of 2500 to 1 out of 20 000, as assessed by ELISPOT and was comparable to the frequencies reported by Lewis et al. (2000) for cancer patients treated with peptide-based vaccines. Here, KLK3 is linked to cancer.